Business ❯ Finance ❯ Market Analysis ❯ Analyst Ratings

Goldman Sachs

Novo Nordisk’s Oral Semaglutide Fails to Slow Alzheimer’s in Dual Phase 3 Trials

Full results will be presented at next week’s CTAD meeting after the company canceled a planned one-year extension.

NuScale Shares Fall After Q3 Miss as Goldman Cuts Target

Baird Lifts Tesla to Outperform With Street-High $548 Target as Focus Turns to Autonomy